BEIJING, China, July 7, 2016 /PRNewswire/ -- Dehaier Medical
Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or the "Company"), which
develops, markets and sells medical devices and wearable sleep
respiratory products in China,
announced on July 5, 2016 that it is
partnering with China Sciences Group (Holding) Co., Ltd. ("China
Sciences") to enter the Chinese pension and health industry by
providing Dehaier's products through China Sciences' elder care
platform. In connection with this announcement, Dehaier, China
Sciences and another supplier, Chia Tai Pharmaceutical Group
("Chia Tai"), have signed a
strategic cooperation agreement to launch the "Elderly Sleep Apnea
Comprehensive Disease Solution Project" (the "Project"). The
Project will leverage China Sciences' "Hui Kang" cloud-based health
management platform to provide Dehaier's and Chia Tai's medical devices to the elderly.
China Sciences is a state-owned enterprise, organized under the
auspices of the Chinese Academy of Sciences ("CAS"). With total
assets of nearly RMB 10 billion,
China Sciences' health pension model enjoys brand and research
support from CAS. The Hui Kang "Internet + Medical Support"
business model will benefit users of Dehaier's smart wearables with
a large, well-received platform. Hui Kang integrates a variety of
localized health and pension service organizations and has grown to
cover more than 300 cities in more than 20 provinces and serve
nearly one million members since the start of October 2014. The Project is expected to reach
approximately 100 health and pension service institutions in 2016,
and 600 in 2017.
Dehaier will provide wearable sleep respiratory products through
the Hui Kang platform. In particular, Dehaier expects to offer its
wearable sleep respiratory products and home ventilator products,
which facilitate diagnosis, therapy, treatment evaluation and case
management. Dehaier expects the Hui Kang platform will increase the
number of potential end users and the quality of contact with those
users. The integration of patient medical information with an
online platform is designed to improve patient treatment outcomes
and reduce elderly end users' personal medical expenses by avoiding
unnecessary or duplicative treatment and medications.
Chia Tai sells a wide range of
products including diabetic special dietary products and chronic
disease management programs. Chia
Tai's end user target market overlaps with Dehaier's, while
its products do not overlap. As a result, Dehaier expects that the
sale of Chia Tai's products through
the Hui Kang platform will benefit both parties by cross-referring
both companies' customers to each other, without selling competing
products.
Dehaier CEO Mr. Chen Ping said:
"As China's population ages, we believe the pension and health
industry is likely to grow. According to the latest statistics of
National Health and Family Planning Commission of the People's Republic of China, China's population over the age of 60 is
expected to grow from approximately 220 million people in 2015 to
about 440 million in 2050. Since between 20% and 40% of the elderly
population suffers from some level of sleep apnea, we expect that a
growing elderly population may increase our industry's potential
market size to nearly $2 billion by
2050."
About Dehaier Medical Systems Ltd.
Dehaier Medical Systems Ltd. was founded in 2003 and
provides comprehensive solutions for people affected by sleep apnea
syndrome, including diagnosis, treatment and efficacy assessment.
The company has advanced production equipment, a sophisticated
R&D team and professional sales and marketing personnel. As the
Chinese public focuses on personal health, Dehaier's wearable sleep
apnea products are poised to enjoy increasing popularity.
Currently, Dehaier has five sales platforms - public hospitals,
private medical examination groups, pension and health management
services institutions, insurance companies and individual users.
Dehaier Medical's technology is based on six patents and eleven
software copyrights. More information may be found at
http://www.dehaier.com.cn.
About China Sciences Group (Holding) Co., Ltd.
China Sciences Group (Holding) Co., Ltd. (China Sciences) is a
large high-tech industry investment and management company
subordinated to Chinese Academy of Sciences. The Group has total
assets of nearly RMB 10 billion. Its
"Hui Kang" health management cloud platform integrated numerous
localized health and pension services organizations. Through
information collection at end data collection terminal and analysis
of big data, it will further assess health and intervene exercise
and diet, targeted to launch the corresponding health care products
and services. While through cloud platform, it can integrate
resources and provide accurate medical resources (genes), expert
advice (light interrogation, expert guidance, etc.), a green
passage for medical treatment and other services, further upgrading
and transforming the ground health care and pension service
agencies, forming a large O2O health service system with cloud
resources + localized high-quality health care services and medical
intermediary services. Since the start of project in October 2014, it now covers more than 300 cities
in more than 20 provinces, involving nearly one million members.
For more information, please visit: http://www.csh.com.cn/.
About Chia Tai Pharmaceutical Group
Chia Tai Pharmaceutical Group is a Health Industry Group
belonging to Thailand's Chia Tai
Group, who are mainly engaged in pharmaceutical, medical and big
health industry business, achieved an annual sales volume of
RMB 15 billion. It has decades of
industrial history in the Chinese market and establishes a good
brand reputation and social reputation in big health field. Chia
Tai Pharmaceutical Group big health industry has the means of
intervention to diabetes, high cholesterol, hypertension and other
chronic disease by functional foods and health management. It is in
a leading domestic position in product development, health
management platform for advice, guidance and other aspects. At the
same time, it also has a corresponding disease group health
management tools and marketing model. For more information, please
visit http://www.cppharm.com/.
For more information, please contact:
Dehaier Medical Systems Limited
Mary Li
+86 10-5166-0080 ext. 211
investors@dehaier.com.cn
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dehaier-medical-systems-ltd-cooperates-with-china-sciences-group-holding-co-ltd-to-enter-chinas-elderly-sleep-apnea-market-300295215.html
SOURCE Beijing Dehaier Medical Technology Co., Ltd.